Form 4: Cullinan Therapeutics' Chief Scientific Officer Sells 8,000 Shares

Jennifer Michaelson, Chief Scientific Officer of Cullinan Therapeutics, sold 8,000 shares of common stock on July 5, 2024, at a weighted average price of $16.33.

Summary

• On July 5, 2024, Jennifer Michaelson, the Chief Scientific Officer of Cullinan Therapeutics, sold 8,000 shares of the company's common stock.
• The sale was executed at a weighted average price of $16.33 per share.
• The transaction was conducted under a pre-arranged trading plan established on January 5, 2024, in accordance with Rule 10b5-1.
• Following the transaction, Michaelson directly owns 123,942 shares of Cullinan Therapeutics' common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting an insider stock sale. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transaction.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider transactions and are closely watched by investors.

Stakeholder Impact

• The stock sale by a key officer may be perceived neutrally or slightly negatively by shareholders, depending on their interpretation of the reasons behind the sale.

Key Dates